CD38 and plasma cell myeloma: Notably, a more advanced patient population was enrolled in this trial since patients were required to have suffered disease progression after three or more LOT, and their myeloma had to be refractory to both IMiDs and PIs, and either refractory or intolerant (or both) to an anti-CD38 antibody.